Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eblasakimab in Moderate-to-Severe Atopic Dermatitis After Dupilumab
2023-508329-28-00Phase 2Authorised
- Sponsor
- ASLAN Pharmaceuticals
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Eblasakimab with Placebo (2 arms). Primary endpoint: Percentage change in EASI score from Baseline to Week 16. Planned start May 2024; status: authorised.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-508329-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508329-28-00.